


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) **Compounds of the A compound of formula I**



wherein

R^1 is H, OH, OA, CN, Hal, COR or CH_2R ,

R is by OH, OA, NH₂, NHA or NA₂,

R^2 and R^3 are H or A,

A is an alkyl group with 1–10 atoms,

X is O or S,

Hal is F, Cl, Br or I






n is 2-6,


m is 1-4

p is 0, 1, 2, 3 or 4


and their salts, enantiomers, solvates, racemates and other mixtures of enantiomers or a salt, enantiomer, solvate, racemate or mixture of enantiomers thereof.

2. (Currently Amended) Compounds A compound according to claim 1, wherein R¹ is F or CN.
3. (Currently Amended) Compounds A compound according to claim 1, wherein R³ is H.
4. (Currently Amended) Compounds A compound according to claim 1, wherein X is S or O.
5. (Currently Amended) Compounds A compound according to claim 1, wherein p is 0 or 1 or 2 or 3 or 4.
6. (Currently Amended) Indol-derivatives A compound according to claim 1 selected from the following group of compounds of the formula I1 to I5:







I1




I2



I3



I4



I5

~~and their salts, solvates, enantiomers and racemates or a salt, solvate, enantiomer or racemate thereof.~~

7. (Currently Amended) ~~Compounds of the A pharmaceutical composition comprising a formula I according to Claim 1 and their or physiologically acceptable salts or solvates as pharmaceutical active compounds salt or solvate thereof and a pharmaceutically acceptable carrier.~~
8. (Cancelled)
9. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as A method of inhibiting serotonin reuptake, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof inhibitor.~~
10. (Currently Amended) ~~Compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates A method of achieving a 5HT1A antagonists antagonistic effect, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.~~
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Currently Amended) ~~Use of compounds according to Claim 1 and/or their physiologically acceptable salts or solvates, enantiomers or racemates for the production of a medicament A method for the treatment of illnesses which can be~~

influenced by the binding of the compound of formula I to the 5-HT receptors,
comprising administering to a host in need thereof a compound according to claim 1
or a salt, solvate, enantiomer or mixture thereof.

15. (Currently Amended) ~~Use of compounds according to Claim 1 and/or their physiologically acceptable salts or solvates, enantiomers or racemates for the production of a medicament A method for the treatment of illnesses of the central nervous system, in particular of mental disorders of the schizophrenia, or type and for the control of psychotic anxiety states, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.~~